Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 August 2004, Vol. 104, No. 4, pp. 1224-1226.
Prepublished online as a Blood First Edition Paper on April 27, 2004; DOI 10.1182/blood-2004-01-0028.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-01-0028v1
104/4/1224    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, V. T.
Right arrow Articles by Antin, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, V. T.
Right arrow Articles by Antin, J. H.
Related Collections
Right arrow Immunobiology
Right arrow Transplantation
Right arrow Immunotherapy
Right arrow Brief Reports
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

TRANSPLANTATION
Brief report

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Vincent T. Ho, David Zahrieh, Ephraim Hochberg, Eileen Micale, Jesse Levin, Carol Reynolds, Steve Steckel, Corey Cutler, David C. Fisher, Stephanie J. Lee, Edwin P. Alyea, Jerome Ritz, Robert J. Soiffer, and Joseph H. Antin

From the Divisions of Medical Oncology and Biostatistics, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Ligand Pharmaceuticals, Inc, San Diego, CA; and Harvard Medical School, Boston MA.

Denileukin diftitox (Ontak), a recombinant protein composed of human interleukin 2 (IL-2) fused to diphtheria toxin, has selective cytotoxicity against activated lymphocytes expressing the high-affinity IL-2 receptor. We conducted a phase 1 study of denileukin diftitox in 30 patients with steroid refractory acute graft-versus-host disease (GVHD). Seven patients received 9 µg/kg intravenously on days 1 and 15; 18 received 9 µg/kg intravenously on days 1, 3, 5, 15, 17, and 19; and 5 received 9 µg/kg intravenously on days 1 to 5 and 15 to 19. Hepatic transaminase elevation was the dose-limiting toxicity (DLT), and dose level 2 was the maximum tolerated dose (MTD). Overall, 71% of patients responded with complete resolution (12 of 24; 50%) or partial resolution (5 of 24; 21%) of GVHD. Eight of 24 patients (33%) are alive at 6.3 to 24.6 months (median, 7.2 months). Denileukin diftitox is tolerable and has promising activity in steroid-refractory acute GVHD. (Blood. 2004;104:1224-1226)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
A. M. Alousi, D. J. Weisdorf, B. R. Logan, J. Bolanos-Meade, S. Carter, N. DiFronzo, M. Pasquini, S. C. Goldstein, V. T. Ho, B. Hayes-Lattin, et al.
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network
Blood, July 16, 2009; 114(3): 511 - 517.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. S Kim
Treatment Options in Steroid-Refractory Acute Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation
Ann. Pharmacother., September 1, 2007; 41(9): 1436 - 1444.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. J. Deeg
How I treat refractory acute GVHD
Blood, May 15, 2007; 109(10): 4119 - 4126.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Vieweg, Z. Su, P. Dahm, and S. Kusmartsev
Reversal of Tumor-Mediated Immunosuppression
Clin. Cancer Res., January 15, 2007; 13(2): 727s - 732s.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
D. Weisdorf
GVHD The Nuts and Bolts
Hematology, January 1, 2007; 2007(1): 62 - 67.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Ghori, K. D. Polder, L. C. Pinter-Brown, A. O. Hoff, R. F. Gagel, S. I. Sherman, and M. Duvic
Thyrotoxicosis after Denileukin Diftitox Therapy in Patients with Mycosis Fungoides
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2205 - 2208.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020